Status:
COMPLETED
Treatment of Melasma Using Q-switched Nd: YAG Laser and Fractional CO2 Laser Separately and in Combination
Lead Sponsor:
Kasr El Aini Hospital
Conditions:
Melasma
Eligibility:
All Genders
18-60 years
Phase:
NA
Brief Summary
* All participants will be divided into 2 groups : Group A \& Group B. * Group A will be subjected to 3 consecutive sessions of Q-switched 1,064 nm Nd: YAG laser to one side of the face \& fractional ...
Eligibility Criteria
Inclusion
- melasma patients above 18 years
Exclusion
- Pregnancy.
- Usage of chemical peeling 1 month prior to the study.
- Isotretinoin intake 6 months prior to the study.
- Any laser procedure related to melasma lesions 1 month prior to the study.
- Active herpetic lesions.
- Any concurrent active skin disease within the treated area.
- Photosensitive skin conditions such as systemic lupus erythematous.
- History of delayed wound healing.
- Keloid formation.
- Bleeding diathesis.
- Medical conditions such as diabetes mellitus \& autoimmune diseases.
Key Trial Info
Start Date :
January 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2019
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT03848013
Start Date
January 1 2017
End Date
June 1 2019
Last Update
January 10 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cairo University Kasr Al Ainy Hospital Dermatology department
Cairo, El Manial, Egypt